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Background 
• New anti-cancer drugs have to show tumour shrinkage in 
phase I/II trials before preceding a phase III trial 
• Fail to identify new drugs that produce disease stabilisation 
(cytostatic) rather than tumour shrinkage (cytotoxic) 
• New approaches required to effectively and efficiently 
identify new cytostatic drugs 
• A potential method would be to measure the tumour growth 
rate in individual patients, tumour growth would be slower 
after staring on an active drug 
– Frequent cross-sectional imaging  
– Monitoring  a patient’s tumour without giving therapy, purely to 
measure its growth rate 
Asymptomatic ovarian cancer patients 
• It is preferable to delay chemotherapy until symptoms 
developed 
• Patients are regularly monitored using the blood serum 
biomarker CA125  
– Rising CA125 is highly correlated with disease progression 
– CA125 could be measured frequently 
• The proposed approach could be applied to asymptomatic 
ovarian cancer patients with their disease monitored using 
CA125 assessment 
CA125 doubling trial 
  
Hypothesis 
In asymptomatic ovarian cancer patients there would  be  
sufficient time to compare the rate of rise of CA125  before and  
after starting  treatment with a novel agent   
– rate of rise of CA125: log linear trend (slope) 
• Sufficient time: at least 3 measures of CA125 level before and after 
starting treatment  
– difference or reduction 
 
 
Design of CA125 doubling trial  
• Eligible asymptomatic ovarian cancer patients registered 
centrally  
• CA125 measured monthly, then 2 weekly after rising until end 
of treatment 
• treatment started  when CA125 > 4xULN  
 
 
 
 
 
 
 
 
 
            monthly                         2 weekly                     2 weekly 
                                            CA125 monitoring   
Design of CA125 doubling trial 
• tamoxifen as the first test agent  
– minimal toxicity compared to chemotherapy  
– proven activity and often offered to such patients 
• Sample size 
– % of patients with log linear CA125 level  over time 
200 patients provide an estimate with a se <3.5%  
– Change of rate of rise CA125 level 
No a priori power model, similar latent growth models with moderate  
effect size (0.3)  have power over 85% with 150 and 90% with 200  
patients 
 
Targeted sample size of 200-250 patients was planned 
Slope analyses 
• Rate of rise of CA125 is measured by the slope, S, of the linear 
regression of ln(CA125) over days 
• Each patient’s rate of rise of CA125 pre-tamoxifen, Spre, 
compared with her own rate in CA125 after starting 
tamoxifen, Son 
• Spre and Son  estimated using the 3 CA125 measurements just 
before  and after starting tamoxifen  
• Mean (Spre- Son) = the magnitude of change in rate of rise of  
CA125 
Analysis population 
• Evaluable group 
– started tamoxifen within 9 months from date of registration  
– at least 3 CA125 assessments before and after starting treatment 
• 9 months group 
– started tamoxifen within 9 months from date of registration 
• Full dataset group 
– patients with at least 3 CA125 assessments before and after starting 
treatment 
Summary of  trial data 
• Between Nov 2003 to July 2010 a total of 207 patients 
registered from 24 sites in the UK 
• 175 patients with at least one CA125 measurement 
• 113 patients received tamoxifen 
– Longest duration between registration and starting tomxifen was over 
3 years and latest assessment was over 4 years after tamoxifen 
• 62 patients in evaluable group 
• 92 patients started treatment within 9 months  
• 80 patients with at least 3 CA125 assessments before and 
after treatment 
Ln(CA125) over time 
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Patients in evaluable group (n=62)   
• 50 (81%) patients with decreasing slope after starting 
tamoxifen 
 
 
 
 
 
• Cohen’s D for change in slope (95% CI) = 0.61 (0.34 to 0.96) 
– a medium to large effect 
– days of CA125 doubled: 28.3 before to 56.5 after treatment 
Mean ln(CA125)/day LCL UCL 
Pre-tamoxifen 0.0245 0.0197 0.0293 
After tamoxifen 0.0123 0.0076 0.0170 
change 0.0122 0.0072 0.0173 
Histogram of slopes 
Patients in 9 months group  
No. of CA125 measurements No. of patients  (n= 92) 
Pre-tamoxifen After 
tamoxifen  
With decreasing 
slope 
 total  
≥ 3 ≥ 3 50 62 
≥ 3 2 5 6 
2 ≥ 3 1 6 
≥ 3 0 or 1 18 
No. of pts with decreasing slope after treatment = 56 (77%) 
All patients with 3 CA125s before 
and after treatment 
Mean (slope) Days (CA125 
doubled) 
Cohen’s D 
Evaluable group patients (n=62) 
Pre-tamoxifen 0.0245 28.3 
After tamoxifen 0.0123 56.5 
change 0.0122 28.2 0.61 
All patients with 3 CA125 assessments before and after (n=80) 
Pre-tamoxifen 0.0220 31.5 
After tamoxifen 0.0106 65.4 
change 0.0114 33.9 0.60    
Summary  
• The rate of rise of CA125 could be measured by the slope of 
log CA125 overtime 
• There is a significant reduction in the rate of rise of CA125 
level after staring tamoxifen 
• The proposed approach could be applied in screening new 
anti-cancer drugs  
– A new agent is worth further investigation if its Cohen’s D is larger 
than 0.60 
– Sample size: 19 patients who had 3 CA125 readings before and after 
treatment required for a power of 80%  for the Cohen’s D=0.60 
Summary of  trial data 
113 patients received tamoxifen with 1563 CA125s 
• 62 patients in evaluable group 
–  Cohen’s D for change in slope = 0.61 (based on 372 CA125s) 
• 80 patients with at least 3 CA125 assessments before and 
after treatment 
– Cohen’s D for change in slope = 0.60 
• the rest 33 (30%) patients? 
 
 
 
Two-piecewise regression model 
log CA125 level for the ith patient at the jth time (days from 
registration), lnCA125ij,    
  
 
 
 
changing point:  time of treatment with δ1 =1 before starting  
                              treatment and δ2 =1 after starting treatment,  
β0, β1, β2: population intercept and slopes of before and after trt  
β0i, β1i, β2i: intercept and slopes for the ith patient 
εij:  random error for the ith patient at the jth time 
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Patient group  
• Evaluable group (62 pts, 917 CA125s)  
• 9 months group (92 pts, 1105 CA125s) 
• All patients received tamoxifen (113 pts, 1563 
CA125s)  
 
 
Results of fitted models 
#pts #CA125s effect estimate SE Pr>|t| 
62 917 pre-trt  0.0200 0.0015 <.0001 
after trt  0.0118 0.0016 <.0001 
Cohen’D =0.52, n=27 diff  0.0083  0.0022  0.0004 
92 1105 pre-trt  0.0216  0.0013 <.0001 
after trt   0.0155 0.0018 <.0001 
Cohen’D =0.38, n=45 diff 0.0061  0.0021  0.0044 
113 1563 pre-trt  0.0194 0.0012  <.0001 
after trt   0.0140 0.0014  <.0001 
Cohen’D =0.36, n=50 diff 0.00536 0.00170  0.0023 
Slope analysis (372 CA125s): Cohen’s D for change in slope  = 0.61 (0.34 to 0.96) 
Histogram of ln(CA125) level (n=113) 
before treatment 
after treatment 
before and after treatment 
Goodness fit of regression model (n=113) 
predicted value against observed                          residuals over time 
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Discussion  
• Magnitude of slope change: piece wise regression  
 
• Analysis population : change points  
– Patients received treated with 9 month (n=92) 
• 24 patients were with less than 3 CA125 assessments after starting treatment 
– Patients received treatment (n=113) 
• 21 patients started treatment after 9 months from registration  
– 175 patients with at least  1 CA125 assessments, ranged (1, 52) with 
median of 10 assessments 
• 62 patients not received treatment (mainly disease progression) 
– 34 patients with more than 6 CA125 assessments 
 
 
 
